Cosmetic cross-reference Noindex: medium evidence

3055-94-5

CAS 3055-94-5

3055-94-5 (CAS 3055-94-5) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
3055-94-5
CAS Number
3055-94-5
UNII
F32E4CB0UJ
InChIKey
FKMHSNTVILORFA-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1651993
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
LAURETH-3
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
LAURETH-3 1310570 SU MTHSPL
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 3055-94-5 used for in pharmaceutical contexts?

3055-94-5 (CAS 3055-94-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 3055-94-5?

No adverse-event association or SIDER side-effect rows are rendered for 3055-94-5 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 3055-94-5 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Laureth-3 with EU status "permitted".

What clinical phase is 3055-94-5 in?

No phase 1-4 clinical development badge is rendered for 3055-94-5 because the matched compound identifier rows do not contain a max-phase value.